James Liao Sells 1,943 Shares of Foxx Development (NASDAQ:FOXX) Stock

Foxx Development Holdings Inc. (NASDAQ:FOXX) CTO James Liao sold 1,943 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $6.15, for a total value of $11,949.45. Following the transaction, the chief technology officer owned 19,431 shares in the company, valued at $119,500.65. This trade represents a 9.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Foxx Development Stock Down 3.6%

NASDAQ:FOXX opened at $5.06 on Friday. The stock’s fifty day moving average is $4.70 and its two-hundred day moving average is $4.52. Foxx Development Holdings Inc. has a 52 week low of $1.71 and a 52 week high of $8.88. The stock has a market capitalization of $35.62 million, a price-to-earnings ratio of -0.74 and a beta of -0.31.

Foxx Development (NASDAQ:FOXX) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($5.19) EPS for the quarter. The business had revenue of $8.67 million during the quarter.

Institutional Trading of Foxx Development

A hedge fund recently raised its stake in Foxx Development stock. JPMorgan Chase & Co. lifted its stake in shares of Foxx Development Holdings Inc. (NASDAQ:FOXX) by 170.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,947 shares of the company’s stock after acquiring an additional 3,121 shares during the quarter. JPMorgan Chase & Co. owned 0.07% of Foxx Development worth $27,000 as of its most recent filing with the Securities and Exchange Commission. 60.44% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Foxx Development from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

About Foxx Development

Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.

Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.